RayzeBio Inc. Common Stoc...

NASDAQ: RYZB · Real-Time Price · USD
62.49
0.01 (0.02%)
At close: Feb 23, 2024, 10:00 PM

RayzeBio Common Stock Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q3 2023 Q4 2022 Q3 2022
Period Ending Sep 30, 2023 Dec 31, 2022 Sep 30, 2022
Revenue
n/a n/a n/a
Cost of Revenue
n/a n/a n/a
Gross Profit
n/a n/a n/a
Operating Income
-60.06M -38.41M -20.95M
Interest Income
6.75M 3.26M 503K
Pretax Income
-53.34M -35.15M -20.45M
Net Income
-53.34M -35.15M -20.45M
Selling & General & Admin
8.3M 4.82M 2.12M
Research & Development
51.76M 33.59M 18.83M
Other Expenses
-30K n/a n/a
Operating Expenses
60.06M 38.41M 20.95M
Interest Expense
n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a
Cost & Expenses
60.06M 38.41M 20.95M
Income Tax Expense
n/a n/a n/a
Shares Outstanding (Basic)
15.4M 27.31M 40.31M
Shares Outstanding (Diluted)
15.4M 27.31M 40.31M
EPS (Basic)
-2.23 -1.05 -0.51
EPS (Diluted)
-2.23 -1.05 -0.51
EBITDA
-58.74M -37.59M -20.55M
EBIT
-60.06M -38.41M -20.95M
Depreciation & Amortization
1.32M 823K 404K